Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Ductal Adenocarcinoma: early-phase trial registry
56 of 85 indexed Pancreatic Ductal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #165 of 28,707 conditions by registered trial count.
85 US clinical trials · 56 currently recruiting · #165 of 28,707 conditions by registered trial count
Pancreatic Ductal Adenocarcinoma: 85 US clinical trials tracked, 56 recruiting.
Pancreatic Ductal Adenocarcinoma is the subject of 85 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 68 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 5 of these trials.
Enrollment posture brief
Registry condition pancreatic-ductal-adenocarcinoma
OPEN 56 | RECR 66% | LATE 1 | EARLY 68 | RANK #165 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Solid Tumor, Adult (66% recruiting · 73 trials)
Pancreatic Ductal Adenocarcinoma lists 56 open slots (66% of 85 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Ductal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Ductal Adenocarcinoma is recruiting above its size-band peers.
56 of 85 indexed trials (65.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Ductal Adenocarcinoma trials is spread across many organizations.
AstraZeneca accounts for 5 of 85 trials (5.9%). 64 distinct sponsors appear on at least one study for this condition label.
-
Typical Pancreatic Ductal Adenocarcinoma enrolment sits around 100 participants.
Median target enrolment is 100 among the 85 trials that report a genuine target (sentinel values excluded). 41 of those (48.2%) plan for fewer than 100 participants.
-
Pancreatic Ductal Adenocarcinoma research is mostly interventional.
72 interventional and 13 observational studies make up this index (84.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
85 total, page 1 of 2
Pancreatic Cancer Early Detection Consortium
Arbor Research Collaborative for Health
NCT04970056
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
NCT06122896
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Mayo Clinic
NCT06151223
UCSF PANC Cyst Registry
University of California, San Francisco
NCT04291651
Pancreatic Cancer Detection Consortium
City of Hope Medical Center
NCT06388967
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines
NCT06445062
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06131840
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02757859
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company
NCT06586515
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Panbela Therapeutics
NCT05254171
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines
NCT06128551
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Bristol-Myers Squibb
NCT07076121
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Oncotelic
NCT06079346
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma
NCT04657068
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma
NCT07094204
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem
NCT07020221
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AstraZeneca
NCT06005493
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
NCT05482893
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
NCT06219941
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Merck Sharp & Dohme
NCT06428409
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT06305247
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Nuvance Health
NCT04406831
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
City of Hope Medical Center
NCT07226154
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Novartis Pharmaceuticals
NCT06562192
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
NCT04851119
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Boehringer Ingelheim
NCT06882746
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT05783622
Study for AZD4360 in Participants With Advanced Solid Tumours
AstraZeneca
NCT06921928
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06710756
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
NCT06218914
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
University of Pennsylvania
NCT07199764
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
NCT06320717
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
Mandana Kamgar, MD
NCT05630989
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Crossignal Therapeutics
NCT06598007
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
NCT07432633
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
University of California, San Francisco
NCT06600906
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT06147037
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
NCT05851924
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Gulam Manji
NCT06048484
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Georgetown University
NCT06015724
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami
NCT07096362
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Northwell Health
NCT07163273
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
NCT05431270
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Baylor College of Medicine
NCT05132504
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
M.D. Anderson Cancer Center
NCT03608631
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
PanTher Therapeutics
NCT06673017
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Global Development
NCT07024615
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology
NCT04150042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 21 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Ductal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Ductal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Ductal Adenocarcinoma page
85 registered trials, 56 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 56 Pancreatic Ductal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Pancreatic Ductal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Ductal Adenocarcinoma condition card totals 85 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.